MaxCyte Stock (NASDAQ:MXCT)
Previous Close
$2.65
52W Range
$2.21 - $5.26
50D Avg
$3.31
200D Avg
$3.89
Market Cap
$270.37M
Avg Vol (3M)
$637.65K
Beta
1.21
Div Yield
-
MXCT Company Profile
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.
MXCT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| LUNG | Pulmonx Corporation |
| KIDS | OrthoPediatrics Corp. |
| CNMD | CONMED Corporation |
| RPID | Rapid Micro Biosystems, Inc. |
| SGHT | Sight Sciences, Inc. |
| NPCE | NeuroPace, Inc. |
| IRMD | IRadimed Corporation |
| SRDX | Surmodics, Inc. |
| ITGR | Integer Holdings Corporation |
| ANIK | Anika Therapeutics, Inc. |
| OFIX | Orthofix Medical Inc. |
| CVRX | CVRx, Inc. |